BioTuesdays

Tag - acute myeloid leukemia

Feature

Mateon taking VDAs in new direction against cancer

By Len Zehr Mateon Therapeutics (NASDAQ:MATN) is developing vascular disrupting agents (VDAs) that selectively disrupt abnormal tumor blood vessels, which supply nutrients to cancer cells, with an initial clinical focus...

September 13, 2016
Feature

Actinium gearing up for pivotal trial in second half

By Len Zehr Actinium Pharmaceuticals (NYSE MKT:ATNM) expects to begin a Phase 3 trial in the second half this year of its Iomab-B drug candidate as a conditioning agent in elderly patients with relapsed/refractory acute...

March 24, 2015